HighTower Advisors’s Immune Design Corp. IMDZ Stock Holding History

HighTower Advisors’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-20,000	Closed	-$26K	–	2500
2018 Q4	$26K	Buy	+20,000	New	+$34.8K	﹤0.01%	2072

Other funds holding IMDZ

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

SAM

Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

HighTower Advisors's IMDZ Position: Q1 2019 in Review

HighTower Advisors sold out of Immune Design Corp. (IMDZ) in Q1 2019, closing a stake of 20,000 shares — an estimated $26K sold.

HighTower Advisors first reported a position in IMDZ in Q4 2018 and held it in 1 quarter. The position peaked at $26K in Q4 2018. 68 funds tracked by Wall St. Rank hold IMDZ as of Q1 2019.

HighTower Advisors reported no remaining Immune Design Corp. position as of Q1 2019 after selling out during the quarter.
HighTower Advisors sold 20,000 Immune Design Corp. shares in Q1 2019, an estimated $26K.
HighTower Advisors first reported a position in Immune Design Corp. in Q4 2018 and held it in 1 quarter.
HighTower Advisors's Immune Design Corp. position peaked at $26K in Q4 2018.
68 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2019.

Based on HighTower Advisors's 13F filing for Q1 2019, filed 15 May 2019.